腎移植感染症マニュアル

出版社： 東京医学社
著者：
発行日： 2013-02-15
分野： 臨床医学：内科  >  腎臓
ISBN： 9784885632204
電子書籍版： 2013-02-15 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,060 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,060 円(税込)

購入する

商品紹介

腎移植への準備はCKD早期から。感染症マネージメントにより腎移植患者の予後は改善。腎臓内科医をはじめとする腎疾患を診る医師に必須の1冊。

目次

  • 腎移植感染症マニュアル

    ―目次―


    総論
    最近の免疫抑制薬における腎移植と感染症
    一般人の感染症と臓器移植後感染症の違いと対応
    腎移植後感染症の発症時期
    腎移植前の評価
    ドナー由来の感染症
    腎移植術に伴う感染症
    特殊な環境下の感染症
    小児に特徴的な感染症

    臓器別
    01　頭部感染症
    02　血流感染症
    03　皮膚軟部組織感染症
    04　胸部感染症
    05　腹部感染症
    06　尿路感染症

    病原体別
    01　サイトメガロウイルス
    02　Epstein-Barrウイルス
    03　単純ヘルペスウイルス，水痘・帯状疱疹ウイルス
    04　ヒトパピローマウイルス
    05　B型肝炎ウイルス
    06　C型肝炎ウイルス
    07　ヒトT細胞白血病ウイルス1型
    08　BKウイルス
    09　JCウイルス
    10　RSウイルス・インフルエンザウイルス
    11　カンジダ
    12　アスペルギルス
    13　クリプトコッカス
    14　ニューモシスチスイロベチイ
    15　結核菌
    16　非結核性抗酸菌
    17　クロストリジウム・ディフィシル
    18　アデノウイルス
    19　ヘリコバクター・ピロリ
    20　ヒト免疫不全ウイルス

    予防その他
    抗菌薬予防投与
    ワクチン接種（成人）
    ワクチン接種（小児）
    トラベル医学
    移植後のペット，食事
    抗菌薬と免疫抑制薬の相互作用
    感染コントロール（市中感染）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.11 掲載の参考文献
1. Fishman JA, Issa NC. Infection in organ transplantation : risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010 ; 24 (2) : 273-83.
PubMed
2. Dummer JS, Thomas LD. Risk factors and approaches to infections in transplant recipients. In : Mandell, Douglas, and Bennett?s Principles and Practice of Infectious Diseases. Churchill Livingstone : Elsevier, 2010 : 3809-19.
 
3. ePocrates. Available from : http://www.epocrates.com/
 
4. Duncan MD, Wilkes DS. Transplant-related immunosuppression. Proc Am Thorac Soc 2005 ; 2 (5) : 449-55.
PubMed
5. The Sanford guide to antimicrobial therapy 2011. 39th ed. Sanford Guide (R)
 
6. 厚生労働科学研究費補助金厚生労働科学特別研究事業「臓器提供施設における院内体制整備に関する研究」臓器提供施設のマニュアル化に関する研究. 臓器提供施設マニュアル平成22年度. Available from : http://www.jotnw.or.jp/jotnw/law_manual/index.html
 
7. IDATENセミナーテキスト編集委員会. 病院内/免疫不全関連感染症診療の考え方と進め方 (IDATEN感染症セミナー). 東京 : 医学書院, 2011.
 
8. Hanna R, Raad I. Diagnosis of catheter-related bloodstream infection. Current Infectious Disease Reports 2005 1 ; 7 (6) : 413-9.
 
9. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007 ; 44 (2) : 159-77.
 
P.15 掲載の参考文献
1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 ; 357 (25) : 2601-14.
PubMed
2. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000 ; 343 : 225-6.
PubMed
3. Southwick FS (編), 青木眞 (監). 感染症診療スタンダードマニュアル 第2版. 東京 : 羊土社, 2011
 
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998 ; 338 (24) : 1741-51.
PubMed
5. Kumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D ; Toronto Invasive Bacterial Diseases Network, McGeer A. Invasive pneumococcal disease in solid organ transplant recipients 10 year prospective population surveillance. Am J Transplant 2007 ; 7 (5) : 1209-14.
 
6. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid- organ transplant recipients : impact and implications for management. Clin Infect Dis 1998 ; 27 (5) : 1266-77.
PubMed
7. Naqvi SA, Hussain M, Askari H, Hashmi A, Hussain Z, Hussain I, Hafiz S, Yazdani I, Rizvi SA. Is there a place for prophylaxis against tuberculosis following renal transplantation? Transplant Proc 1992 ; 24 (5) : 1912.
 
8. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996 ; 61 (2) : 211-5.
PubMed
9. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients : report of five cases and review of the literature. Rev Infect Dis 1983 ; 5 (2) : 216-26.
PubMed
10. Schulman LL, Scully B, McGregor CC, Austin JH. Pulmonary tuberculosis after lung transplantation. Chest 1997 ; 111 (5) : 1459-62.
PubMed
11. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994 ; 58 (3) : 301-6.
PubMed
P.22 掲載の参考文献
1. Halloran PF. Immunosuppresive drug for kidney transplantation. N Engl J Med 2004 ; 351 : 2715-29.
 
2. Freeman RB, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999 ; 68 : 1107-111.
PubMed
3. Singh N. Mycobacterium tuberculosis infection in solid organ transplant recipients : Impact and implications for management. Clin Infect Dis 1998 ; 27 : 1266-77.
PubMed
4. Kalil AC. Metaanalysis : The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. An Intern Med 2005 ; 143 : 870-80.
PubMed
5. Green M. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998 ; 66 : 1641-4.
PubMed
6. Ahn J. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2008 ; 14 : 1603-8.
PubMed
7. Gonzalez-Perez MP. Human T-cell leukemia virus type I infection in various recipients of transplants from the same donor. Transplantion 2003 ; 75 : 1006-11.
PubMed
8. TakahashiM, et al. Enhance of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003 ; 21 : 3843-53. PMID : 12922118
 
P.28 掲載の参考文献
1. Ison MG, Hager J, Blumberg E, Burdick J, Carney K, Cutler J, Dimaio JM, Hasz R, Kuehnert MJ, Ortiz-Rios E, Teperman L, Nalesnik M. Donor-derived disease transmission events in the United States : data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009 ; 9 (8) : 1929-35.
PubMed
2. Rogers NM, Peh CA, Faull R, PannellM, Cooper J, Russ GR. Transmission of toxoplasmosis in two renal allograft recipients receiving an organ from the same donor. Transpl Infect Dis 2008 ; 10 : 71-4.
PubMed
3. Humar A, MorrisM, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, Schweitzer E, Ganz S, Caliendo A, Orlowski JP, Wilson B, Kotton C, Michaels M, Kleinman S, Geier S, Murphy B, Green M, Levi M, Knoll G, Segev D, Brubaker S, Hasz R, Lebovitz DJ, Mulligan D, O'Connor K, Pruett T, Mozes M, Lee I, Delmonico F, Fischer S. Nucleic acid testing (NAT) of organ donors : is the 'best' test the right test? A consensus conference report. Am J Transplant 2010 ; 10 (4) : 889-99.
 
4. Ison MG. The epidemiology and prevention of donor-derived infections. Adv Chronic Kidney Dis 2009 ; 16 (4) : 234-41.
PubMed
5. Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006 ; 81 (12) : 1658-61.
PubMed
6. Widell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV) -infected patients transplanted with an HCV-infected kidney. Transplantation 1995 ; 60 (7) : 642-7.
PubMed
7. Natov SN, Lau JY, Ruthazer R, Schmid CH, Levey AS, Pereira BJ. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1999 ; 56 (2) : 700-6.
 
8. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002 ; 74 (4) : 427-37.
PubMed
9. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH,Marcellin P,Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S ; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011 ; 364 (25) : 2405-16.
 
10. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001 ; 1 (2) : 185-91.
 
11. Cortes NJ, Afzali B, MacLean D, Goldsmith DJ, O?Sullivan H, Bingham J, Lewis DA, MacMahon E, Tong CY, Koffman G. Transmission of syphilis by solid organ transplantation. Am J Transplant 2006 ; 6 (10) : 2497-9.
PubMed
12. McCoy GC, Loening S, BraunWE, Magnusson MO, Banowsky LH, McHenry MC. The fate of cadaver renal allografts contaminated before transplantation. Transplantation 1975 ; 20 (6) : 467-72.
PubMed
13. Satoi S, Bramhall SR, Solomon M, Hastings M, Mayer AD, de Goyet JV, Buckels JA, McMaster P, Mirza DF. The use of liver grafts from donors with bacterial meningitis. Transplantation 2001 ; 72 (6) : 1108-13.
PubMed
14. Kumar A, Humar A. The AST Handbook of Transplant Infections. America Society of Transplantation. 93-6.
 
15. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005 ; 293 (22) : 2756-61.
 
16. Grossi PA, Fishman JA ; AST Infectious Disease Community of Practice. Donor-derived infections in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S19-26.
 
P.33 掲載の参考文献
1. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection. Infect Control Hosp Epidemiol 1999 ; 20 : 247-74.
 
2. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement project : national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006 ; 43 : 322-30.
PubMed
3. Condon RE, Schulte WJ, Malangoni MA, et al. Effectiveness of a surgical wound surveillance program. Arch Surg 1983 ; 118 : 303-7.
PubMed
4. Horan TC, Gaynes RP, MartoneWJ, et al. CDC definitions of nosocomial surgical site infections, 1992 : a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992 ; 13 : 606-8.
PubMed
5. Horan TC, Gaynes RP, MartoneWJ, et al. CDC definitions of nosocomial surgical site infections, 1992 : a modification of CDC definitions of surgical wound infections. Am J Infect Control 1992 ; 20 : 271-4.
PubMed
6. 針原康, 小西敏郎. SSIサーベイランスをしませんか-SSIサーベイランス研究会の活動-. INFECTION CONTROL 2005 ; 14 : 978-81.
Medical*Online
7. Ramos A, Asensio A, Mun'ez E, et al. Incisional surgical site infection in kidney transplantation. Urology 2008 ; 72 : 119-23.
 
8. Lynch RJ, Ranney DN, Shijie C, et al. Obesity, surgical site infection, and outcome following renal transplantation. Ann Surg 2009 ; 250 : 1014-20.
PubMed
P.38 掲載の参考文献
1. Burdette SD. The AST Handbook of Transplant Infections, 1st ed. In : Kumar D, Humar A (eds). New York : Blackwell Publishing, 2011 : 131-6.
 
2. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009 ; 48 : 772-86.
PubMed
3. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment : case series and comprehensive review of the literature. Medicine 2010 ; 89 : 308-18.
PubMed
4. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab : systematic review and meta-analysis. BMC Med 2011 ; 9 : 36.
PubMed
5. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Osto?r AJ. Non-infectious pulmonary toxicity of rituximab : a systematic review. Rheumatology 2012 ; 51 : 653-62.
 
6. Everly MJ, Terasaki PI, Hopfield J, Trivedi HL, Kaneku H. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation 2010 ; 90 : 1493-8.
PubMed
7. Baseler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009 ; 183 : 6145-50.
 
8. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of allotantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant 2011 ; 30 : 1320-6.
PubMed
9. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001 ; 43 : 182-6.
PubMed
10. Cadili A, de Gara C. Complications of splenectomy. Am J Med 2008 ; 121 : 371-5.
PubMed
11. Moffett SL. Overwhelming postsplenectomy infection : managing patients at risk. JAAPA 2009 ; 22 : 36-9.
PubMed
12. Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980 ; 244 (21) : 2423.
PubMed
13. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991 ; 114 : 924-9.
 
14. Schonermarck U, Kauke T, Jager G, Habicht A, Wendler T, Andrassy J, Guba M, Stangl M, Fischereder M. Effect of apheresis for ABO and HLA desensitization on anti-measles antibody titers in renal transplantation. J Transplant 2011 ; Epub 2011 Dec 8.
 
15. Keating GM, Lyseng-Williamson KA, McKeage K. Eculizumab : a guide to its use in paroxysmal nocturnal hemoglobinuria. Bio Drugs 2012 ; 26 : 125-30.
 
16. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA,Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009 ; 9 : 231-5.
PubMed
17. Ling X, Xiong J, Liang W, Schroder PM, Wu L, Ju W, Kong Y, Shang Y, Guo Z, He X. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012 ; 93 : 737-43.
PubMed
18. Niwa M, Miwa Y, Kuzuya T, Iwasaki K, Haneda M, Ueki T, Katayama A, Hiramitsu T, Goto N, Nagasaka T,Watarai Y, Uchida K, Nakao A, Kobayashi T. Stimulation index for PCNA mRNA in peripheral blood as immune function monitoring after renal transplantation. Transplantation 2009 ; 87 : 1411-4.
PubMed
P.43 掲載の参考文献
1. Dharnidharka VR, Caillard S, Agodoa LY, et al. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006 ; 81 : 1662-7.
PubMed
2. NAPRTCS (on line) https://web.emmes.com/study/ped/annlrept/2010_Report.pdf
 
3. Martin-Pena A, Cordero E, Fijo J, et al. Prospective study of infectious complications in a cohort of pediatric renal transplant recipients. Transplantation 2000 ; 69 : 1617-23.
 
4. Vikas R, Dharnidharka VR, Tejani AH, et al. Post-transplant lymphoproliferative disorder in the United States : young Caucasian males are at highest risk. Am J Transplant 2002 ; 2 : 993-8.
 
5. Penna FJ, Elder JS. CKD and bladder problems in children. Adv Chronic Kidney Dis 2011 ; 18 : 362-9.
PubMed
6. Feber J, Spatenka J, Seeman T, et al. Urinary tract infections in pediatric renal transplant recipients-a two center risk factors study. Pediatr Transplant 2009 ; 13 : 881-6.
PubMed
7. Coulthard MG, Keir MJ. Reflux nephropathy in kidney transplants, demonstrated by dimercaptosuccinic acid scanning. Transplantation 2006 ; 82 : 205-10.
PubMed
8. Lapidus-Krol E, Shapiro R, Amir J, et al. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Pediatr Transplant 2010 ; 14 : 753-60.
PubMed
9. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients : Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005 ; 79 : 85-90.
PubMed
10. Hebert D, Sulivan EK. Malignancy and posttransplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients : a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998 ; 2 (Suppl 1) : 57 (Abstract).
 
11. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001 ; 97 : 1165-71.
PubMed
12. Collins MH, Montone KT, Leahey AM, et al. Post-transplant lymphoproliferative disease in children. Pediatr Transplant 2001 ; 5 : 250-7.
PubMed
13. Flaegstad T, Traavik T, Kristiansen BE. Age-dependent prevalence of BKvirus IgG and IgM antibodies measured by enzyme-linked immunosorbent assays (ELISA). J Hyg 1986 ; 96 : 523-8.
 
14. Andrews CA, Shah KV, Dantel RW, et al. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis 1988 ; 158 : 176-81.
 
15. Fogeda M, Munoz P, Luque A. Cross-sectional study of BK virus infection in pediatric kidney transplant recipients. Pediatr Transplant 2007 ; 11 : 394-401.
PubMed

臓器別

P.53 掲載の参考文献
1. Levitz RE. Herpes simplex encephalitis : a review. Heart Lung 1998 ; 27 (3) : 209-12.
PubMed
2. Mandell GL, Bennett JE, DOLIN R. Mandell, Douglas, and Bennett?s Principles and Practice of Infectious Diseases, 7th ed. Churchill Livingstone, 2010 : 1266.
 
3. van de Beek D, Patel R, Daly RC, McGregor CG, Wijdicks EF. Central nervous system infections in heart transplant recipients. Arch Neurol 2007 ; 64 (12) : 1715-20.
PubMed
4. Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients : epidemiologic, microbiologic, and clinical features. Clin Transplant 2002 ; 16 (6) : 419-24.
 
5. Senzolo M, Ferronato C, Burra P. Neurologic complications after solid organ transplantation. Transpl Int 2009 ; 22 (3) : 269-78.
PubMed
6. Singh N, Husain S. Infections of the central nervous system in transplant recipients. Transplant Infect Dis 2000 ; 2 : 101.
PubMed
7. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005 ; 106 (8) : 2641-5.
PubMed
8. Mandell GL, Bennett JE, DOLIN R. Mandell, Douglas, and Bennett?s Principles and Practice of Infectious Diseases, 7th ed. Churchill Livingstone, 2010 : 3199-207.
 
9. Mamelak AN, Obana WG, Flaherty JF, Rosenblum ML. Nocardial brain abscess : treatment strategies and factors influencing outcome. Neurosurgery 1994 ; 35 (4) : 622-31.
PubMed
10. Khin-Sane-Win, Matsumura T, Kumagai S, Uga S, Konishi E. Prevalence of antiboy to Toxoplasma gondii in Hyogo prefecture, Japan : comparison at a 10-year interval. Kobe J Med Sci 1997 ; 43 : 159-68.
 
11. Campbell AL, Goldberg CL, Magid MS, Gondolesi G, Rumbo C, Herold BC. First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation. Transplantation 2006 ; 81 (3) : 408-17.
PubMed
12. Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, Woodle ES. Posttransplant lymphoproliferative disorder : significance of central nervous system involvement. Transplant Proc 2005 ; 37 (2) : 954-5.
PubMed
13. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients : variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001 ; 7 (3) : 375-81.
PubMed
14. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis : an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002 ; 4 (4) : 183-8.
PubMed
15. Bowden RA. Transplant Infections 3rd ed. Ljungman P, Snydman DR (eds) ; Chapter 17, Lippincott Williams & Wilkins, 2010 : 226.
 
16. Dockrell DH. Human herpesvirus 6 : molecular biology and clinical features. J Med Microbiol 2003 ; 52 : 5-18.
PubMed
17. Mizuno S, Zendejas IR, Reed AI, Kim RD, Howard RJ, Hemming AW, Schain DC, Soldevila-Pico C, Firpi RJ, Fujita S. Listeria monocytogenes following orthotopic liver transplantation : central nervous system involvement and review of the literature. World J Gastroenterol 2007 ; 13 (32) : 4391-3.
PubMed
18. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore) 1998 ; 77 (5) : 313-36.
 
19. Wildemann B, Ehrhart K, Storch-Hagenlocher B, Meyding-Lamade U, Steinvorth S, Hacke W, Haas J. Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology 1997 ; 48 (5) : 1341-6.
PubMed
P.57 掲載の参考文献
1. Harbarth S, Ferriere K, Hugonnet S, et al. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002 ; 137 : 1353-9.
PubMed
2. Silva M Jr, Marra AR, Pereira CA, et al. Bloodstream infection after kidney transplantation : epidemiology, microbiology, associated risk factors, and outcome. Transplantation 2010 ; 90 : 581-7.
PubMed
3. McClean K, Kneteman N, Taylor G, et al. Comparative risk of bloodstream infection in organ transplant recipients. Infect Control Hosp Epidemiol 1994 ; 15 : 582-4.
PubMed
4. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection : 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009 ; 49 : 1-45.
 
5. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000 ; 132 : 391-402.
PubMed
6. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals : analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 ; 39 : 309-17.
PubMed
7. 鈴木利保 (訳). 血管内留置カテーテル, ICUブック, 稲田英一 (監訳), 東京 : メディカル・サイエンス・インターナショナル, 2008 : 112-8.
 
8. 中村守男 (訳). 血管内カテーテル関連感染症, 感染症診療スタンダードマニュアル, 青木眞 (監), 東京 : 羊土社, 2007 : 251-5.
 
9. Marshall DA, Mertz PM, Eaglstein WH. Occlusive dressings. Does dressing type influence the growth of common bacterial pathogens? Arch Surg 1990 ; 125 : 1136-9.
PubMed
10. Kidney Disease : Improving Global Outcomes (KDIGO) TransplantWork Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009 ; 9 (Suppl 3) : S1-155.
 
11. 藤本卓司. 血管内カテーテル関連感染症, 感染症レジデントマニュアル, 東京 : 医学書院, 2004 : 119-24.
 
12. O'Grady NP, AlexanderM, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011 ; 52 : 162-93.
 
P.64 掲載の参考文献
1. IDATENセミナーテキスト編集委員会 (編). 市中感染症診療の考え方と進め方IDATEN感染症セミナー, 東京 : 医学書院, 37-54.
 
2. 青木眞. 皮膚・軟部組織感染症. レジデントのための感染症診療マニュアル第2版, 東京 : 医学書院, 2008 : 757-818.
 
3. Bisno AL, Stevens DL. Streptococcal infections in skin and soft tissues. N Engl J Med 1996 ; 334 : 240-5.
PubMed
4. Swartz MN. Clinical practice : cellulitis. N Engl J Med 2004 ; 350 : 904-12.
PubMed
5. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis) : case-control study. BMJ 1999 ; 318 : 1591-4.
PubMed
6. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999 ; 29 : 1483-8.
PubMed
7. Hook EW III, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986 ; 146 : 295-7.
 
8. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med 1988 ; 148 : 2451-2.
PubMed
9. Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011 ; 52 (3) : e18-55.
 
10. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent softtissue infections. J Infect 1991 ; 22 : 37.
PubMed
11. Sjoblom AC, Eriksson B, Jorup-Ronstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993 ; 21 : 390.
 
12. Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997 ; 25 : 685.
PubMed
13. Lloveras J, Peterson PK, Simmons RL, Najarian JS. Mycobacterial infections in renal transplant recipients. Seven cases and a review of the literature. Arch Intern Med 1982 ; 142 (5) : 888-92.
 
14. Mazen S, Lawrence E, Daniel WP. Skin infections after hemopoietic stem cell or solid organ transplantation. Raleigh A. Bowden. Per Ljungman David R. Snydman. Transplant Infections 3rd ed. 2010 : 203-13.
 
15. Zuckerman R, Wald A, AST Infec Dis Com. Human simplex virus infections in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S104-7.
 
16. Pergam SA, Limaye AP, AST Infec. Dis. Com. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S108-15.
 
17. Viner K, Perella D, Lopez A, Bialek S, Newbern C, Pierre R, Spells N,Watson B. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 2012 ; 205 (9) : 1336-41.
PubMed
18. Kwak EJ, Julian K, AST Infec Dis Com. Human papillomavirus infection in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S151-60.
 
P.70 掲載の参考文献
1. Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates : Etiology, clinical manifestations, and management. Medicine (Baltimore) 1980 ; 59 : 206.
 
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 ; 357 : 2601.
PubMed
3. Chang FY, Singh N, Gayowski T, et al. Fever in liver transplant recipients : Changing spectrum of etiologic agents. Clin Infect Dis 1998 ; 26 : 59.
PubMed
4. Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta : an emergency department-based study. Can Respir J 2005 ; 12 : 139.
PubMed
5. Wunderink RG, Waterer GW. Community-acquired pneumonia : pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 2004 ; 18 : 743.
PubMed
6. Southwick FS (編), 青木眞, 喜舎場朝和 (監). 感染症診療スタンダードマニュアル 第2版. 東京 : 羊土社, 2011.
 
7. Mandell GL, et al. Principles and practice of infectious diseases. 7th ed. Churchill Livingstone : Elsevier, 2009, Chapter 312, table 312-3.
 
8. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia : a population-based case-control study. Arch Intern Med 2007 ; 167 : 950.
PubMed
9. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004 ; 170 (1) : 22-48.
PubMed
10. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients : P. jirovecii is contagious to the susceptible host. Transplantation 2009 ; 88 (3) : 380-5.
 
11. Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med 2005 ; 26 (4) : 691-705.
PubMed
12. White DA. Aspergillus pulmonary infections in transplant recipients. Clin Chest Med 2005 ; 26 (4) : 661-74.
PubMed
13. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients : impact and implications for management. Clin Infect Dis 1998 ; 27 (5) : 1266-77.
PubMed
14. Bowden RA, Ljungman P, Snydman DR. Transplant Infections 3rd ed. (eds), Lippincott Williams&Wilkins, 2010 : 187-96.
 
15. Cordonnier C, Cunningham I. Pneumonia after hematopoietic stem cell or solid organ transplantation. Transplant Infections. 3rd ed Lippincott Williams & Wilkins, 2010 : 187-202.
 
16. Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus : clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature. Nephrol Dial Transplant 2007 ; 22 : 363.
 
17. Filippone EJ, Carson JM, Beckford RA, Jaffe BC, Newman E, Awsare BK, Doria C, Farber JL. Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient : a case report. Transplant Proc 2011 ; 43 (7) : 2792-7.
 
P.77 掲載の参考文献
1. 多発性嚢胞腎診療指針. 日腎会誌 2011 ; 53 (4) : 556-83.
 
2. Danna PL, Urban C, Bellin E, Rahal JJ. Role of Candida in pathogenesis of antibiotic-associated diarrhea in elderly inpatients. Lancet 1991 ; 337 (8740) : 511-4.
PubMed
3. Andersen LI, Frederiksen HJ, Appleyard M. Prevalence of esophageal Candida colonization in a Danish population : special reference to esophageal symptoms, benign esophageal disorders, and pulmonary disease. J Infect Dis 1992 ; 165 (2) : 389-92.
 
4. Hackman RC, Wolford JL, Gleaves CA, Myerson D, Beauchamp MD, Meyers JD, McDonald GB. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods. Transplantation 1994 ; 57 (2) : 231-7.
PubMed
5. Yagi T, Karasuno T, Hasegawa T, Yasumi M, Kawamoto S, Murakami M, Uosima N, Nakamura H, Hiraoka A, Masaoka T. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation : importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000 ; 25 (9) : 1003-5.
PubMed
6. Arabia FA, Rosado LJ, Huston CL, Sethi GK, Copeland JG 3rd. Incidence and recurrence of gastrointestinal cytomegalovirus infection in heart transplantation. Ann Thorac Surg 1993 ; 55 (1) : 8-11.
PubMed
7. Spencer GD, Shulman HM, Myerson D, Thomas ED, McDonald GB. Diffuse intestinal ulceration after marrow transplantation : a clinicopathologic study of 13 patients. Hum Pathol 1986 ; 17 (6) : 621-33.
PubMed
8. Stelzmueller I, Dunst KM, Hengster P, Wykypiel H, Steurer W, Wiesmayr S, Margreiter R, Bonatti H. A cluster of rotavirus enteritis in adult transplant recipients. Transpl Int 2005 ; 18 (4) : 470-4.
PubMed
9. Dominguez Fernandez E, Albrecht KH, Heemann U, Kohnle M, Erhard J, Stoblen F, Eigler FW. Prevalence of diverticulosis and incidence of bowel perforation after kidney transplantation in patients with polycystic kidney disease. Transpl Int 1998 ; 11 (1) : 28-31.
PubMed
10. Sonsino E, Mouy R, Foucaud P, Cezard JP, Aigrain Y, Bocquet L, Navarro J. Intestinal pseudoobstruction related to cytomegalovirus infection of myenteric plexus. N Engl J Med 1984 ; 311 (3) : 196-7.
PubMed
11. Grant RM, Weitzman SS, Sherman CG, SirkinWL, Petric M, Tellier R. Fulminant disseminated Varicella Zoster virus infection without skin involvement. J Clin Virol 2002 ; 24 (1-2) : 7-12.
 
12. Sterling RK. Management of gastrointestinal disease in liver transplant recipients. Gastrointest Endosc Clin N Am 200 ; 11 (1) : 185-97.
 
13. Mayoral JL, Loeffler CM, Fasola CG, Kramer MA, Orrom WJ, Matas AJ, Najarian JS, Dunn DL. Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. Arch Surg 1991 ; 126 (2) : 202-6.
PubMed
14. Reed EC, Wolford JL, Kopecky KJ, Lilleby KE, Dandliker PS, Todaro JL, McDonald GB, Meyers JD. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebocontrolled trial. Ann Intern Med 1990 ; 112 (7) : 505-10.
PubMed
15. Stylianos S, Chen MH, Treat MR, LoGerfo P, Rose EA. Colonic lymphoma as a cause of massive rectal bleeding in a cardiac transplant recipient. J Cardiovasc Surg 1990 ; 31 (3) : 315-7.
 
16. Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation : a 3-yr sequential study. Clin Transplant 2002 ; 16 (3) : 163-7.
PubMed
P.80 掲載の参考文献
1. Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation : A retrospective review at two US transplant centers. Clin Transplant 2005 ; 19 : 230-5.
 
2. Giral M, Pascuariello G, Karam G, et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int 2002 ; 61 : 1880-6.
PubMed
3. Pelle G, Vimont S, Levy PP, et al. Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant 2007 ; 7 : 899-907.
PubMed
4. Audard V, Amor M, Desvaux D, et al. Acute graft pyelonephritis : A potential cause of acute rejection in renal transplant. Transplantation 2005 ; 80 : 1128-30.
PubMed
5. Memikoglu KO, Keven K, Sengul S, Soypacaci Z, Erturk S, Erbay B. Urinary tract infections following renal transplantation : A singlecenter experience. Transplant Proc 2007 ; 39 : 3131-4.
PubMed
6. Vidal E, Torre-Cisneros J, Blanes M, Montejo M, Cervera C, Aguado JM, Len O, Carratala J, Cordero E, Bou G, Munoz P, Ramos A, Gurgui M, Borrell N, Fortun J ; on behalf of the Spanish Network for Research in Infectious Diseases (REIPI). Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis 2012 doi : 10.1111/j. 1399-3062.2012.00744. x.
 
7. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998 ; 338 : 1741-51.
PubMed
8. Mathew TH, Kincaid-Smith P, Vikraman P. Risks of vesicoureteric reflux in the transplanted kidney. N Engl J Med 1977 ; 297 : 414-8.
PubMed
9. Dupont PJ, Psimenou E, Lord R, Buscombe JR, Hilson AJ, Sweny P. Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation 2007 ; 84 : 351-5.
PubMed
10. Moradi M, Abbasi M, Moradi A, Boskabadi A, Jalali A. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J 2005 ; 2 : 32-5.
 
11. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000 ; 11 (Suppl 15) : S1-86.
 

病原体別

P.90 掲載の参考文献
1. Humar A et al. American Society of Transplantation Recommendation for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 ; 6 : 262-74.
PubMed
2. Pegues DA, et al. Handbook of kidney transplanation, 5th ed. 2009.
 
3. 大黒徹, 武本眞清, 白木公康. サイトメガロウイルス感染症の基礎研究. 今日の移植 2010 ; 23 (2) : 180-9.
 
4. Rayes N, Seehofer D, Lullius SG, et al. Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation : A prospective study. Ann Transplant 2005 ; 10 : 23.
PubMed
5. Schroeder R, Michelon T, Fagundes I, et al. Antigenemia for cytomegalovirus in renal transplantation : Choosing a cut off for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 2005 ; 37 : 2781-3.
 
6. The TH, Van der Gij W, Van den Berg AP, et al. Cytomegalovirus antigenemia. Rev Inf Dis 1990 ; 12 (Suppl 7) : s737-44.
 
7. Masuho Y, et al. Human monoclonal antidodies neutralizing human cytomegalovirus. J Gen Virol 1987 ; 68 : 1457-61.
 
8. 渡井至彦. 腎移植における長期生着を目指してウイルス感染. 今日の移植 2010 ; 23 : 90-5.
 
9. Piiparinen H, Hockerstedt K, Gronhagen-Riska, et al. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004 ; 30 : 258.
PubMed
10. Gerna G, Baldanti F, Torsellini M, et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenemia cutoff for guiding preemptive therapy in transplant recipients ; A randomized study. Antivir Ther 2007 ; 12 : 63.
PubMed
11. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safty of 200 days valganciclovir prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010 ; 10 (5) : 1228-37.
 
12. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with Ganciclovir : A mata-analysis comparing prophylactic and preemptive therapies. Clin Inf Dis 2006 ; 43 : 869-80.
 
13. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with Valganciclovir : A systemic review. Am J Transplant 2008 ; 8 : 2111-8.
 
14. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 ; 5 : 218-27.
PubMed
15. Kotton CN, Kumar D, Caliendo AM, et al. International Consensus Guidelines in the management of cytomegalovirus in solid organ transplantation. Transplantation 2010 ; 89 : 779-95.
PubMed
16. Humar A, Snydman D. AST Infectious Disease Community of Practice. Cytomagalovirus in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S78-86.
 
17. KDIGO Clinical practice Guideline for the care of kidney transplant recipients. Am J Transplant 2009 ; 9 (Suppl 3) : S46.
 
18. 日本臨床腎移植学会ガイドライン作成委員会. 腎移植後サイトメガロウイルス感染症の診療ガイドライン 2011, 東京 : 日本医学館, 2011.
 
19. Ozaki K, et al. The use of sirolimus in ganciclovir-resistant cytomagalovirus infections in renal transplant recipients. Clin Transplant 2007 ; 21 : 675.
 
P.96 掲載の参考文献
1. Sullivan JL, Luzuriaga K. Viology of Epstein-Barr virus. UpToDateR 20.2
 
2. Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant 1998 ; 2 : 56-63.
PubMed
3. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults : report of 230 cases from French Registry. Am J Transplant 2006 ; 6 : 2735-42.
PubMed
4. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001 ; 3 : 70-8.
PubMed
5. Special Issue : KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Epstein-Barr virus and post-transplant lymphoproliferative disease. Am J Transplant 2009 ; 9 (Suppl 3) : S44-58.
 
6. Allen U, Preiksaitis J, the AST InfectiousDiseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S87-96.
 
7. Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003 ; 163 (17) : 1997.
PubMed
8. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988 ; 133 (1) : 173.
 
9. Rajakariar R, BhattacharyyaM, Norton A, et al. Post transplant T-cell lymphoma : a case series of four patients from a single unit and review of the literature. Am J Transplant 2004 ; 4 (9) : 1534.
PubMed
10. Krzysztof M, Bartosz F, Bogna Z, et al. Post-transplant lymphoproliferative disorder in view of the new WHO classification : a more rational approach to a protean disease? Nephrol Dial Transplant 2010 ; 25 : 2089-98.
 
11. Rowe DT, Webber S, Schauer EM, et al. Epstein-Barr virus load monitoring : Its role in the prevention and management of post-transplant lymphoproliferative disease. Transplant Infect Dis 2001 ; 3 : 79-87.
PubMed
12. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of post-transplant lymphoproliferative disorder : Result of a two-arm prospective trial. Am J Transplant 2008 ; 8 : 1016-24.
 
13. Preiksaitis JK, Cockfield SM. Epstein-Barr virus infection and lymphoproliferative disorders after transplantation. Bowden RA, Ljungman P, Snydman DR (eds), Transplant Infections., 3rd ed. Philadelphia : Lippincott Williams & Wilkins, 2010 : 362-90.
 
14. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997 ; 63 (9) : 1200.
PubMed
15. Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 2011 ; 24 (1) : 193.
PubMed
P.101 掲載の参考文献
1. Zuckerman R, Wald A, the AST Infectious Diseases Community of Practice. Herpes simplex virus infections in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S104-7.
 
2. Pergam SA, Limaye AP, the AST Infectious Diseases Community of Practice. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S108-15.
 
3. Klein RS. Epidemiology of herpes simplex virus type 1 infection. UpToDate 2012 ; 19.
 
4. Albrecht MA. Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection. UpToDate 2012 ; 19.3.
 
5. Prentice HG, Hann IM. Antiviral therapy in the immunocompromised patient. Br Med Bull 1985 ; 41 : 367-73.
PubMed
6. 国立感染症研究所ホームページ (http://idsc.nih.go.jp/index-j.html) 感染症サーベイランス感染症発生動向調査.
 
7. Albrecht MA. Epidemiology and pathogenesis of varicella-zoster virus infection : Herpes zoster. UpToDate 2012 ; 19.3.
 
8. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991 ; 7 : 435-7.
PubMed
9. Humar A, Snydman D, the AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S78-86.
 
10. Kidney Disease : Improving Global Outcomes (KDIGO) TransplantWork Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009 ; 9 (Suppl 3) : S1-155.
 
11. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012 ; 366 : 34-43.
PubMed
12. Goto N, Kawaguchi T, Watarai Y, et al. A vaccine to prevent herpes zoster in kidney transplantation. Am J Transplant 2011 ; 11 (Suppl 2) : 43.
 
P.106 掲載の参考文献
1. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986 ; 58 : 611-6.
PubMed
2. Paternoster DM, Cdster M, Resente C, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008 ; 40 : 1877-880.
 
3. Dyall-Smith D, Trowell H, Dyall-Smith ML. Benign human papilloma virus infection in renal transplant recipients. Int J Dermatol 1991 ; 30 : 785-9.
PubMed
4. Euvrard S, Kanitakis J, Chardonnet Y, et al. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 1997 ; 133 : 175-8.
PubMed
5. zur Hausen H. Papilloma viruses causing cancer : evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000 ; 92 : 690.
 
6. Grulich AE, van Leeuwen MT, Falster MO, Vajcic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients : A meta-analysis. Lancet 2007 ; 370 : 59-67.
 
7. Penn I. Post-transplant malignancy : The role of immunosuppression. Drug Saf 2000 ; 23 : 101-13.
PubMed
8. Kahan BD, Knight R, Schoenberg L et al. Ten years of sirolimus therapy for human renal transplantation : The University of Texas at Houston experience. Transplant Proc 2003 ; 35 (Suppl 3) : 25S-34.
 
9. Sillman FH, Sentovich S, Shaffer D. Anogenital neoplasia in renal transplant patients. Ann Transplant 1997 ; 2 : 59-66.
PubMed
10. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. CA cancer J Clin 2002 ; 52 : 342.
PubMed
11. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral lad of humanpapilloma virus 16 as a determinant for development of cervical carcinoma in situ : A nested case-control study. Lancet 2000 ; 355 : 2189-93.
 
12. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral lad of human papillomavirus 16 and risk of cervical carcinoma in situ : A nested case-control study. Lancet 2000 ; 355 : 2194-98.
 
13. Kaplan JE, Benson C, et al. Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009 ; 58 (RR-4) : 1-207.
 
14. Avery RK, Michaels M. Update on immunization in solid organ transplant recipients : What clinicians need to know. Am J Transplant 2008 ; 8 : 9-14.
PubMed
P.112 掲載の参考文献
1. Maynard JE. Hepatitis B : global importance and need for control. Vaccine 1990 ; 8 (Suppl) : S18.
 
2. Stevens CE, Beasley RP, Tsui J, LeeWC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975 ; 292 : 771.
 
3. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987 ; 92 : 1844.
PubMed
4. Kobayashi M, Arase Y, Ikeda K, et al. Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 2003 ; 38 : 656.
PubMed
5. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, Saito A, LaBrecque J, Port FK, Young EW. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents : the DOPPS. Kidney Int 2003 ; 63 (6) : 2222-9.
PubMed
6. Chow KM, Szeto CC, Wu AK, et al. Continuous ambulatory peritoneal dialysis in patients with hepatitis B liver disease. Perit Dial Int 2006 ; 26 : 213.
PubMed
7. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation : meta-analysis of observational studies. Am J Transplant 2005 ; 5 (12) : 2913-21.
PubMed
8. Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol 2011 ; 6 (6) : 1481-7.
PubMed
9. Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, Guttmann RD. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987 ; 44 (3) : 369-76.
PubMed
10. Knoll A, Pietrzyk M, Loss M, et al. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen : Low risk of HBV reactivation. Transplantation 2005 ; 79 : 1631-3.
PubMed
11. Levitsky J, Doucette K ; AST Infectious Diseases Community of Practice. Viral hepatitis in solid organ transplant recipients. Am J Transplant 2009 ; 4 (Suppl) : S116-30.
 
12. Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002 ; 36 : 1246-52.
PubMed
13. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 ; 130 : 678.
 
14. Wirth S. Antiviral treatment of hepatitis B following solid organ transplantation in children. Pediatr Transplant 2006 ; 10 : 271-5.
PubMed
15. Mast EE,Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM Jr, Janssen RS, Ward JW ; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States : recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II : immunization of adults. MMWR Recomm Rep 2006 ; 55 (RR-16) : 1-33 ; quiz CE1-4.
 
16. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, Kiaii M, Taylor PA, Levin A. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization : earlier is better. Am J Kidney Dis 2003 ; 42 (6) : 1184-92.
PubMed
17. Barclay S, Pol S, Mutimer D, et al. Erratum to 'The management of chronic hepatitis B in the immunocompromised patient : Recommendations fromasingle topic meeting' [J Clin Virol 2008 ; 41 (4) : 243-254]. J Clin Virol 2008 ; 42 : 104-15.
 
P.119 掲載の参考文献
1. Mathurin P, Mouquet C, Poynard T. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999 ; 29 : 257-63.
 
2. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Analysis 2005 ; 18 : 52-61.
 
3. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999 ; 131 : 174-81.
 
4. Kidney Disease : Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008 ; 73 (Suppl 109) : S1-S99.
 
5. 透析患者のC型ウイルス肝炎治療ガイドライン. 透析会誌 2011 ; 44 : 481-531.
 
6. Schiavon LL, Schiavon JL, Filho RJ, et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007 ; 46 : 307-14.
PubMed
7. Cruzado JM, Casanovas-Taitavull T, Torras J. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003 ; 3 : 357-60.
 
8. Gursoy M, Guvener N, Koksal R. Impact of HCV infection in development of posttransplantation diabetes mellitus in renal allograft patients. Transplant Proc 2000 ; 32 : 561-72.
 
9. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C : a randomized study. Gut 2007 ; 57 : 525-30.
PubMed
10. Zeniya M, Yokoyama K, Imamura N, et al : Significance of interferon-b for the treatment of hepatitis C virus infection in hemodialyzed patients. Hepatol Res 2010 ; 40 : 862-9.
 
11. Pageaux GP, Hilleret MN, Garrigues V, et al. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients : an open pilot study. Transpl Int 2009 ; 22 : 562-7.
PubMed
12. Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Transplantation of kidneys from HCV-positive donors : a safe strategy. J Nephrol 2003 ; 16 : 617-25.
PubMed
13. 斉藤純, 矢澤浩治, 角田洋一, 他. HCV-RNA陽性ドナーに対しIFN療法を行い生体腎移植を施行した2例. 移植 2006 ; 41 : 273-6.
 
P.122 掲載の参考文献
1. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia : clinical and hematologic features of 16 cases. Blood 1977 ; 50 : 481-92.
PubMed
2. Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia : antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981 ; 78 : 6476-80.
 
3. Osame M, Matsumoto M, Usuku K, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol 1987 ; 21 : 117-22.
PubMed
4. 厚生労働省科学研究費補助金新型インフルエンザ等新興・再興感染症研究事業「本邦におけるHTLV-1感染及び関連疾患の実態調査と総合対策」研究班 (主任研究者山口一成). 平成21年度総括報告書.
 
5. 難病情報センター. HTLV-1 関連脊髄症 (HAM), http://www.nanbyou.or.jp/entry/212
 
6. HTLV-I 母子感染予防対策保健指導マニュアル (改訂版), http://www.mhlw.go.jp/bunya/kodomo/boshi-hoken16/dl/05.pdf
 
7. Saito M, Matsuzaki T, Satou Y, et al. In vivo expression of the HBZ gene of HTLV-I correlates with proviral load, inflammatory markers and disease severity in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2009 ; 6 : 19.
 
8. 猪瀬悠理, 秋山茂雄, 望月温子, 他. 生体腎移植後にHTLV-1関連脊髄症を発症した1例. 臨床神経 2010 ; 50 : 241-5.
 
9. (社) 日本臓器移植ネットワークホームページ. ドナー適応基準, http://www.jotnw.or.jp/jotnw/law_manual/pdf/donor%20adjustment%20standard.pdf
 
10. 日本臨床腎移植学会ホームページ. 生体腎移植ガイドライン, http://www.jscrt.jp/pdf_file/guideline.pdf
 
11. Nakamura N, Tamaru S, Ohshima K, et al. Prognosis of HTLV-I-positive renal transplant recipients. Transplant Proc 2005 ; 37 : 1779-82.
PubMed
12. 細川直登. HTLV-I抗体. 感度と特異度からひもとく感染症診療のDecision Making, 東京 : 文光堂, 254-7.
 
13. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop 2010 ; 50 : 9-25.
PubMed
P.126 掲載の参考文献
1. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999 ; 67 : 103-9.
PubMed
2. Hirsch HH, Randhawa P and AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am J Transplant 2009 ; 9 : S136-46.
PubMed
3. Hirsch HH, Knowles W, Dikenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002 ; 347 : 488-96.
 
4. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002 ; 13 : 2145-51.
PubMed
5. Kamney E, Mihatsch MJ. Plasma cell infiltrates in polyoma nephropathy. Transplant Intern ISSN 2010 ; 23 : 397-406.
 
6. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000 ; 15 : 324-32.
 
7. Batal I, Franco ZM, Shapiro R, et al. Clinicopathologic analysis of patients with BK viruria and rejection like graft dysfunction. Hum Pathol 2009 ; 40 : 1312-9.
PubMed
8. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy : update on antiviral strategies. Transplant Infect Dis 2006 ; 8 : 95-101.
PubMed
9. 武田朝美, 両角國男, 打田和治. 腎移植の進歩 (4) 腎移植とウイルス感染. 日腎会誌 2004 ; 46 : 661-6.
 
10. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation : interdisciplinary analysis and recommendations. Transplantaion 2005 ; 79 : 1277-86.
 
P.132 掲載の参考文献
1. Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971 ; 1 (7712) : 1257-60.
PubMed
2. Lisa M. Epidemiology of JC and BK virus infection. 2012 : 1-3, Up To Date
 
3. Ricciardiello L, Laghi L, Ramamirtham P, et al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 2000 ; 119 : 1228.
PubMed
4. Monaco MC, Jensen PN, Hou J, et al. Detection of JC virus DNA in human tonsil tissue : evidence for site of initial viral infection. J Virol 1998 ; 72 : 9918.
PubMed
5. Kunitake T, Kitamura T, Guo J, et al. Patient-to-child transmission is relatively common in the spread of the human polyomavirus JC virus. J Clin Microbiol 1995 ; 33 : 1448.
 
6. Supha K, Raymund R. JC virus infection after transplantation : Beyond the classic progressive multifocal leukoencephalopathy? Gastroenterol Hepatol 2007 ; 3 (1) : 74-6.
 
7. Kantarci G, Eren Z, Demirag A, et al. JC virus-associated nephropathy in a renal transplant recipient and comparative analysis of previous cases. Transpl Infect Dis 2011 ; 13 : 89-92.
 
8. Kazory A, Ducloux D, Chalopin JM, et al. The first case of JC virus allograft nephropathy. Transplantation 2003 ; 76 (11) : 1653-5.
PubMed
9. Igor J. Progressive multifocal leukoencephalopathy : Epidemiology, clinical manifestations, and diagnosis. 2012 : 1-16, Up To Date
 
10. Igor J. Progressive multifocal leukoencephalopathy : Prognosis and treatment. 2012 : 1-11, Up To Date
 
11. Beppu M, Kawamoto M, Nukuzuma S, Kohara N. Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. Intern Med 2012 ; 51 (10) : 1245-7.
 
12. Kishida S, Tanaka K. Mefloquine treatment in a patient suffering from progressive multifocal leukoencephalopathy after umbilical cord blood transplant. Intern Med 2010 ; 49 (22) : 2509-13.
 
13. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009 ; 53 (5) : 1840-9.
PubMed
P.137 掲載の参考文献
1. Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002 ; 2 : 287-91.
PubMed
2. Ison MG, Michaels MG. RNA respiratory infections in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S166-72.
 
3. Lopez-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients : a prospective study. Transplantation 2007 ; 84 : 851-6.
PubMed
4. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997 ; 102 : 2-9. discussion 25-6.
 
5. Nichols WG, Guthrie KA, Corey L, et al. Influenza infections after hematopoietic stem cell transplantation : risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004 ; 39 : 1300-6.
PubMed
6. van Elden LJ, van Karaaij MG, Niihuis M, et al. Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Clin Infect Dis 2002 ; 34 : 177-83.
 
7. Centers for Disease Control and Prevention. Prevention and control of influenza. MMWR 2005 ; 54 (RR08) : 1-40.
 
8. Michael B, Rothenberg MD, Sarah D. Complications of seasonal and pandemic influenza. Clitical Care Med 2010 ; 38 : 4 : e91-7.
 
9. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients : combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000 ; 25 : 751-5.
PubMed
10. Committee of the WHO consultation : Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010 ; 362 ; 18 : 1708-19.
PubMed
11. 大曲貴夫, 上田晃弘, 藤田崇宏, 他. 免疫不全者の呼吸器感染症. 東京 : 南山堂, 2011 : 285-93.
 
12. Nickerson CL, Jakob GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun 1990 ; 58 : 2809-14.
 
13. Andrea D, John AG, Saul K, et al. Vaccinations for adult solid-organ transplant recipients : current recommendations and protocols. Clin Microbiol Rev 2003 ; 16 : 357-64.
 
14. Scharpe J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008 ; 8 : 332-7.
PubMed
P.142 掲載の参考文献
1. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals : analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 ; 39 : 309.
PubMed
2. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995 ; 20 : 1526.
PubMed
3. Murphy JW, Bistoni F, Deepe GS, Blackstock RA, Buchanan K, Ashman RB, Romani L, Mencacci A, Cenci E, Fed'Ostiani C, Del Sero G, Calich VL, Kashino SS. Type 1 and type 2 cytokines : from basic science to fungal infections. Med Mycol 1998 ; 36 (Suppl 1) : 109-18.
 
4. Kirkpatrick CH. Chronic mucocutaneous candidiasis. J Am Acad Dermatol 1994 ; 31 (3 Pt 2) : S14-7.
 
5. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007 ; 45 : 305-20.
PubMed
6. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999 ; 1 : 229-36.
PubMed
7. Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of proven invasive candidiasis : Disseminated versus single organ infection. Diagn Microbiol Infect Dis 1993 ; 17 : 103-9.
PubMed
8. MitsutakeK, Miyazaki T, Tashiro T, et al. Enolase antigen, mannan, Cand-Tec antigen and b-glucan in patients with candidemia. J Clin Microbiol 1996 ; 34 : 1918-21.
 
9. 細川直登. 感度と特異度からひもとく感染症診療のDecision Making. カンジダ抗原. 東京 : 文光堂, 2012 : 206-8.
 
10. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter, clinical evaluation of the (1- > 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 ; 41 : 654-9.
PubMed
11. Obayashi T, Negishi K, Svzvki T, Funata N. Reappraisal of the serum (1- > 3) -beta-D-glucan based assay for the diagnosis of invasive fungal infections-A study based on autopsy cases from 6 years. Clin Infect Dis 2008 ; 46 : 1864-70.
 
12. Odabasi Z,Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections : Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004 ; 39 : 199-205.
PubMed
13. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients : Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000 ; 181 : 309-16.
PubMed
14. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD ; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 ; 48 (5) : 503-35.
 
15. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ. Amphotericin B lipid complex for invasive fungal infections : analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 ; 26 (6) : 1383-96.
PubMed
16. Kauffman CA, Carver PL. Update on echinocandin antifungals. Semin Respir Crit Care Med 2008 ; 29 (2) : 211-9.
PubMed
17. Safdar N, Slattery WR, Knasinski V, Gangnon RE, Li Z, Pirsch JD, Andes D. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis 2005 ; 40 (10) : 1413-21.
PubMed
18. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, Lee JY, Dismukes WE. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000 ; 30 (1) : 14-8.
 
19. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients : a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000 ; 70 : 112-6.
 
P.148 掲載の参考文献
1. 渋谷和俊, 他. 深在性真菌症の病態と診断. 今日の移植 2009 ; 22 : 368.
Medical*Online
2. 青木眞. レジデントのための感染症診療マニュアル (第2版). 東京 : 医学書院, 2008 : 1107.
 
3. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996 ; 100 : 171-8.
PubMed
4. Munoz P, Giannella M, Burillo A, Bouza E. Aspergillus and other mold infections after solid organ transplant. Bowden RA, Ljungman P, Snydman DR (eds) Transplant Infections 3rd ed. 2010 : 554-66.
 
5. Singh N, Husain S ; AST Infectious Diseases Community Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S180-91.
 
6. 高倉俊二. 日本における固形臓器移植後の侵襲性アスペルギルス症の現状. シンポジウム「アスペルギルス症への挑戦～診断から治療まで～」第9回真菌症フォーラム, 東京.
 
7. 堀口祐司. 侵襲性アスペルギルス症の早期診断におけるβ-グルカン測定およびガラクトマンナン抗原測定法の有用性. 感染症学誌 2004 ; 78 : 566.
 
8. 前崎繁文. 深在性真菌症. Jpn J Antibiot 2005 ; 58 : 368.
 
9. Walsh TJ, et al. Treatment of Aspergillosis : Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 ; 46 : 327.
 
10. Veroux M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc 2007 ; 39 : 1838.
PubMed
11. Raoul Herbrecht, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 ; 347 : 408.
PubMed
12. Denning DW, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Inf Dis 2002 : 34 : 563.
 
13. Marc A. von Mach, et al. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clinical Pharmacol 2006 ; 6 : 6.
PubMed
14. Kuypers DR, et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. Transplantation 2006 ; 81 : 1750
 
P.155 掲載の参考文献
1. 泉川公一. クリプトコックス感染症の治療戦略 (脳髄膜炎以外) 非免疫不全患者における肺クリプトコックス症の治療 ; IDSAガイドライン真菌症治療のUP-TO-DATE, 医薬ジャーナル 2010 : 291-7.
 
2. Mandell : Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Chapter 263, 3287-303.
 
3. Pappas PG, Kaufmann C, Alexander B, et al. Prospective surveillance of invasive fungal infections (lfls) among organ transplant recipients (OTRs) in the U. S. 2001-2006. 47th Interscience Conference on Anticrobial Agents and Chemotherapy, Chicago, September 17-20, 2007.
 
4. Saag MS, Graybill RJ, Larsen RA, et al. Practice guideline for the management of cryptococcal disease. Clin Infec Dis 2000 ; 30 : 710-8.
 
5. Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994 ; 32 (7) : 1680-4.
PubMed
6. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S. Pulmonary cryptococcosis in solid organ transplant recipients : clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008 ; 46 (2) : e12-8.
PubMed
7. Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients : Clinical relevance of abnormal neuroimaging findings. Transplantation 2008 ; 56 : 647-51.
 
8. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and Cryptococcal meningitis. Clin Infect Dis 2000 ; 30 : 47-54.
PubMed
9. Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis and infectious disease. Adv Exp Med Biol 2008 ; 635 : 135-46.
PubMed
P.159 掲載の参考文献
1. Pifer LL, Hughes WT, Stagno S, et al. Pneumocystis carinii infection : evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978 ; 61 (1) : 35-41.
PubMed
2. Wakefield AE, Lindley AR, Ambrose HE, et al. Limited asymptomatic carriage of Pneumocystis jirovecii in human immunodeficiency virus-infected patients. J Infect Dis 2003 ; 187 (6) : 901-8.
 
3. Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011 ; 13 : 551-8.
PubMed
4. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989 ; 140 (5) : 1204-9.
PubMed
5. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1- > 3) beta-Dglucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009 ; 49 (7) : 1128-31.
 
6. de Boer MG, Gelinck LB, van Zelst BD, et al. b-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients : a prospective study. J Infect 2011 ; 62 (1) : 93-100.
 
7. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011 ; 11 : 76.
PubMed
8. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006 ; 3 : CD006150.
PubMed
9. Martin SI, Fishman JA ; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S227-33.
 
10. Kidney Disease : Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009 ; 9 (Suppl 3) : S1-155.
 
11. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995 : comparison of HIV-associated cases to other immunocompromised states. Chest 2000 ; 118 (3) : 704-11.
PubMed
12. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus : U. S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999 ; 48 (RR-10) : 1-66.
 
13. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients : P. jirovecii is contagious to the susceptible host. Transplantation 2009 ; 88 (3) : 380-5.
 
14. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008 ; 46 (3) : 966-71.
PubMed
15. Phipps LM, Chen SC, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia : Lessons from a cluster in kidney transplant recipients. Transplantation 2011 ; 92 (12) : 1327-34.
PubMed
P.164 掲載の参考文献
1. WHO Global tuberculosis control 2011 http://www.who.int/tb/publications/global_report/en/index.html
 
2. 日本結核病学会. 結核治療ガイドライン 2009
 
3. Julia'n Torre-Cisneros, et al. Tuberculosis after solid-organ transplant : incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009 ; 48 (12) : 1657.
 
4. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005 ; 40 : 581-7.
PubMed
5. 日本結核病学会予防委員会. クォンティフェロンRTBゴールドの使用指針. 結核 2011 ; 86 (10) : 839-44.
 
6. Subramanian A. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S57-62.
 
7. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients : impact and implications for management. Clin Infect Dis 1998 ; 27 (5) : 1266.
PubMed
8. 後藤憲彦. 腎移植と結核-潜在性結核感染者に対する移植後モニタリング. 結核 2011 ; 86 (2) : 102-5.
 
9. Mycobacterium tuberculosis. Am J Transplant 2004 ; 4 (Suppl 10) : 37-41.
 
10. European best practice guidelines for renal transplantation. Section IV : Long-term management of the transplant recipient. IV. 7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002 ; 17 (Suppl 4) : 39-43.
 
11. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients : the evidence for prophylaxis. Transplantation 2010 ; 15 ; 90 (7) : 695-704.
 
P.169 掲載の参考文献
1. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy : The new mycobacteria of the 1990s. Clin Microbiol Rev 2003 ; 16 : 319-54.
PubMed
2. Horsburgh CR Jr. Epidemiology of Mycobacterium avium complex. Korvick JA, Benson CA (eds) Mycobacterium avium complex infection : progress in research and treatment. New York : Marcel Dekker, 1996 : 1-22.
 
3. Doucette K, Fishman JA. Nontuberculosis mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004 ; 38 : 1428-39.
 
4. Fan MH, Hadjiliadis D. Incidence and management of mycobacterial infection in solid organ transplant recipients. Curr Infect Dis Rep 2009 ; 11 : 216-22.
PubMed
5. Dorman S, Subramanian A, AST Infectious Diseases Community of Practice. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S63-9.
 
6. C. Fordham von Reyn. Nontuberculous mycobacteria. Anthony S Fanci, Eugene Braunwald (eds) Harrison's Principles of Internal Medicine 17th ed. New York : McGraw-Hill, 2008 : 1027-32.
 
7. 青木眞. 非定型抗酸菌症. レジデントのための感染症診療マニュアル 第2版, 東京 : 医学書院, 2008 : 1075-83.
 
8. Griffith DE, Aksamit T, Brown-Elliot B, et al. An official ATS/IDSA statement : Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 ; 175 : 367-416.
 
9. Brown BA, Wallace RJ Jr. Infections due to nontuberculous mycobacteria. Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas and Bennet's principles and practice of infectious diseases. 6th ed, Philadelphia : Churchill-Livingstone, 2005 : 3191-8.
 
10. Griffith DE, Wallace RJ Jr, et al. Overview of nontuberculous mycobacterial infections in HIV-negative patients. UpToDate(R) ver 18.2.
 
11. Clark NM. Treatment of non-tuberculous Mycobacterium infections. Deepali K, Atul H (eds) The AST Handbook of Transplant Infections West Sussex, WILEY-BLACKWELL, 2011 : 77-8.
 
12. Avery RK, Michaelsb MG, the AST Infectious Diseases Community of Practice. Strategies for safe living following solid organ transplantation. Am J Transplant 2009 ; 9 (Suppl 4) : S252-7.
 
P.177 掲載の参考文献
1. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of psudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009 ; 44 : 74.
PubMed
2. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada : patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010 ; 50 : 194.
PubMed
3. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhea. Lancet 1998 ; 351 : 633-6.
PubMed
4. Munoz P, Giannella M, Alcala L, et al. Clostridium difficile associated diarrhea in heart transplant recipients : Is hypogammaglobulinemia the answer? J Heart Lung Transplant 2007 ; 26 : 907-14.
PubMed
5. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity : Identification of novel risk factors. Clin Infect Dis 2007 ; 45 : 1543-9.
 
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults : 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010 ; 31 : 431-55.
 
7. Dubberke ER, Riddle DJ and AST Infections Disease Community of Practice. Clostridium difficile in solid organ transplant recipients : Am J Transplant 2009 ; 9 (Suppl 4) : S35-40.
 
8. Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. Gastroenterol Clin North Am 2006 ; 35 : 315-35.
PubMed
9. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection : a systematic review. Int J Infect Dis 2009 ; 13 : 663-7.
PubMed
10. Enache-Angoulvant A, Hennequin C, et al. Invasive Saccharomyces infection : a comprehensive review. Clin Infec Dis 2005 ; 173 : 167-70.
 
11. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007 ; 245 : 267.
PubMed
12. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006 ; 8 : 149.
PubMed
13. Surveillance or community-associated Clostridium difficile--Connecticut, 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep 2008 ; 57 (13) : 340.
 
14. Gould LH, Limbago B, et al. Clostridium difficile in food and domestic animals : a new foodborne pathogen? Clin Infect Dis 2010 ; 51 (5) : 577-82.
PubMed
P.181 掲載の参考文献
1. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008 ; 21 : 704-15.
PubMed
2. Ison MG, Green M. Adenovirus in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S161-5.
 
3. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006 ; 43 : 331-9.
PubMed
4. Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992 ; 5 : 262-74.
PubMed
5. Komiya T, Goto N, Takeda A, et al. A case of acute rejection with adenovirus infection after ABO-incompatible kidney transplantation. Clin Transplant 2009 ; 23 (Suppl 20) : 27-30.
 
6. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc 2004 ; 36 : 3025-7.
PubMed
7. 大塚聡樹. 尿中アデノウイルスに対する免疫クロマト法によるアデノウイルス抗原検出の検討. 移植 2009 ; 44 : 304.
 
8. Humar A, Kumar D, Mazzulli T, et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant 2005 ; 5 : 2555-9.
PubMed
9. 山口裕. 移植腎のウイルス感染性腎症. In : 移植腎病理アトラス. 東京 : 東京医学社, 2005 : 267-75.
 
10. Saquib R, Melton LB, Chandrakantan A, et al. Disseminated adenovirus infection in renal transplant recipients : the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis 2009 ; 12 : 77-83.
PubMed
11. Lim AK, Parsons S, Ierino F. Adenovirus tubulointerstitial nephritis presenting as a renal allograft space occupying lesion. Am J Transplant 2005 ; 5 : 2062-6.
PubMed
12. Emovon OE, Lin A, Howell DN, et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation : successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant 2003 ; 18 : 2436-8.
PubMed
13. Abe S, Miyamura K, Oba T, et al. Oral ribavirin for severe adenovirus infection after allogeneic marrow transplantation. Bone Marrow Transplant 2003 ; 32 : 1107-8.
PubMed
P.185 掲載の参考文献
1. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007 ; 71 : 438-41.
PubMed
2. Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kawano Y. Clinical characteristics and survival in end-stage renal disease patients with arteriosclerosis obliterans. Am J Nephrol 2002 ; 22 : 422-8.
PubMed
3. Gur G, Boyacioglu S, Gul C, et al. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant 1999 ; 14 : 2688-91.
PubMed
4. Neithercut WD, Rowe PA, el Nujumi AM, Dahill S, McColl KE. Effect of Helicobacter pylori infection on intragastric urea and ammonium concentrations in patients with chronic renal failure. J Clin Pathol 1993 ; 46 : 544-7.
PubMed
5. Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol 1987 ; 22 : 372-6.
PubMed
6. Sezer S, Ibis A, Ozdemir BH, et al. Association of Helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc 2004 ; 36 : 47-9.
PubMed
7. Sotoudehmanesh R, Ali Asgari A, Ansari R, Nouraie M. Endoscopic findings in end-stage renal disease. Endoscopy 2003 ; 35 : 502-5.
PubMed
8. Prakash J, Agrawal BK. Upper gastrointestinal mucosal lesions in chronic renal failure. Indian J Gastroenterol 1991 ; 10 : 131-2.
PubMed
9. Gheissari A, Rajyaguru V, Kumashiro R, Matsumoto T. Gastrointestinal hemorrhage in end stage renal disease patients. Int Surg 1990 ; 75 : 93-5.
PubMed
10. Tsai CJ, Hwang JC. Investigation of upper gastrointestinal hemorrhage in chronic renal failure. J Clin Gastroenterol 1996 ; 22 : 2-5.
PubMed
11. Khedmat H, Ahmadzad-Asl M, Amini M, et al. Gastroduodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc 2007 ; 39 : 1003-7.
PubMed
12. Milito G, Taccone-Gallucci M, Brancaleone C, et al. Assessment of the upper gastrointestinal tract in hemodialysis patients awaiting renal transplantation. Am J Gastroenterol 1983 ; 78 : 328-31.
PubMed
13. Milito G, Taccone-Gallucci M, Brancaleone C, et al. The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int 1985 ; 17 (Suppl) : S157-60.
PubMed
14. Musola R, Franzin G, Mora R, Manfrini C. Prevalence of gastroduodenal lesions in uremic patients undergoing dialysis and after renal transplantation. Gastrointest Endosc 1984 ; 30 : 343-6.
PubMed
15. Wee A, Kang JY, Ho MS, Choong HL, Wu AY, Sutherland IH. Gastroduodenal mucosa in uraemia : endoscopic and histological correlation and prevalence of Helicobacter-like organisms. Gut 1990 ; 31 : 1093-6.
PubMed
16. Sugimoto M, Yamamoto Y. Review of Helicobacter pylori infection and chronic renal failure. Therap Apher Dialy 2011 ; 15 : 1-9.
 
17. Hwang IR, Kodama T, Kikuchi S, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002 ; 123 : 1793-803.
PubMed
18. Wesdorp RI, Falcao HA, Banks PB, Martino J, Fischer JE. Gastrin and gastric acid secretion in renal failure. Am J Surg 1981 ; 141 : 334-8.
PubMed
19. Gladziwa U, Haase G, Handt S, et al. Prevalence of Helicobacter pylori in patients with chronic renal failure. Nephrol Dial Transplant 1993 ; 8 : 301-6.
PubMed
20. Chey WD, Wong BC ; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 ; 102 (8) : 1808-25.
PubMed
21. Tsukada K, Miyazaki T, Katoh H, et al. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients. Scand J Gastroenterol 2002 ; 37 : 1265-8.
PubMed
22. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice a day triple therapy for the eradication on Helicobacter pylori. Aliment Pharmacol Ther 1996 ; 10 : 1029-33.
 
23. Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999 ; 13 : 163-8.
PubMed
24. Lamouliatte H, Cayla R, Megraud F. Treatment of Helicobacter pylori infection. Rev Prat 2000 ; 50 : 1442-5.
PubMed
P.191 掲載の参考文献
1. http://www.who.int/hiv/pub/progress_report2011/en/index.html (Accessed on December 13, 2012).
 
2. 平成23 (2011) 年エイズ発生動向年報 (http://api-net.jfap.or.jp/status/2011/11nenpo/nenpo_menu.htm)
 
3. Moore RD, Keruly JC, Bartlett JG. Improvement in the health of HIV-infected persons in care : reducing disparities. Clin Infect Dis 2012 ; 55 (9) : 1242-51.
PubMed
4. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003 ; 9 (6) : 727-8.
PubMed
5. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-SadrWM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fa?tkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006 ; 355 (22) : 2283-96.
 
6. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-SadrWM, Kirk O, Dabis F, LawMG, Pradier C, DeWit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus : the D : A : D study. Arch Intern Med 2006 ; 166 (15) : 1632-41.
 
7. AD Study Group, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, Thie?baut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007 ; 356 (17) : 1723-35.
 
8. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Inferior clinical outcome of the CD4+cell count-guided antiretroviral treatment interruption strategy in the SMART study : role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008 ; 197 (8) : 1145-55.
 
9. HIV感染症治療研究会. HIV感染症「治療の手引き」 (http://www.hivjp.org/guidebook/hiv_15.pdf)
 
10. International Antiviral Society-USA (https://www.iasusa.org/)
 
11. Gupta SK, Eustace JA,Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA. Guidelines for the management of chronic kidney disease in HIV-infected patients : recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005 ; 40 (11) : 1559.
 
12. Kimmel PL, Umana WO, Simmens SJ, Watson J, Bosch JP. Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. Kidney Int 1993 ; 44 (2) : 373.
PubMed
13. Ortiz C, Meneses R, Jaffe D, Fernandez JA, Perez G, Bourgoignie JJ. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988 ; 34 (2) : 248.
PubMed
14. Perinbasekar S, Brod-Miller C, Pal S, Mattana J. Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol 1996 ; 16 : 280.
PubMed
15. Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis 2000 ; 36 : 574.
PubMed
16. Tourret J, Tostivint I, du Montcel ST, Bragg-Gresham J, Karie S, Vigneau C, Guiard-Schmid JB, Deray G, Bagnis CI. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 2006 ; 1 (6) : 1241-7.
PubMed
17. Lang P, Niaudet P. Update and outcome of renal transplant patients with human immunodeficiency virus. The Groupe Cooperatif de Transplantation de I'lle de France. Transplant Proc 1991 ; 23 : 1352.
 
18. Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. Transplantation 1990 ; 49 : 354.
PubMed
19. Roland MS, Carlson L. Liver and kidney transplantation in HIV-infected patients : A preliminary multi-site experience. 9th Conference on Retroviruses and Opportunistic Infections ; February 24-28, 2002 ; Seattle, Washington. Abstract 655.
 
20. Stock P, Roland M, Carlson L, et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001 ; 33 : 3646.
PubMed
21. Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients : a pilot safety and efficacy study. Transplantation 2003 ; 76 : 370.
PubMed
22. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004 ; 15 : 1633.
PubMed
23. El Sayegh S, Keller MJ, Huprikar S, Murphy B. Solid organ transplantation in HIV-infected recipients. Pediatr Transplant 2004 ; 8 : 214.
PubMed
24. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005 ; 67 : 1622.
PubMed
25. Qiu J, Terasaki PI, Waki K, et al. HIV-positive renal recipients can achieve survival rates similar to those of HIVnegative patients. Transplantation 2006 ; 81 : 1658.
PubMed
26. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients : 1- and 3-year outcomes. Am J Transplant 2008 ; 8 : 355.
PubMed
27. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010 ; 363 : 2004.
PubMed
28. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIVinfected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009 ; 9 : 1946-52.
PubMed
29. Kaplan JE, Benson C, Holmes KK, Brookes JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of American. MMWR ; 2009 ; 58 (RR04) : 1-198.
 
30. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005 ; 67 : 1622-1629.
PubMed
31. Kumar MSA, Khan SM, Ranganna K, Malat GE, Kumar AMS, Jacobson JM. In HIV+patients with end stage renal disease (ESRD) kidney transplantation significantly prolongs long-term patient survival compared to chronic dialysis treatment. Am J Transplant 2008 ; 8 (Suppl 2) : 179.
 

予防その他

P.197 掲載の参考文献
1. National Collaboration Centre for Chronic Conditions. Tuberculosis, clinical diagnosis and management. London : Royal College of Physicians, 2006.
 
2. Jasmer RM. Clinical practice. latent tuberculosis infection. N Engl J Med 2002 ; 347 : 1860.
PubMed
3. Nolan CM. Hepatotoxicity associated with isoniazid preventive therapy : a 7-year survey from a public health tuberculosis clinic. JAMA 1999 ; 281 : 1014.
PubMed
4. OestreicherR. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc 1954 ; 70 : 504.
PubMed
5. Sterling TR. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl JMed 2011 ; 365 : 2155.
 
6. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992 ; 145 : 36.
 
7. AsplerA. Impact of treatment completion, intolerance and adverse events on health system costs in a randmised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010 ; 65 : 582.
PubMed
8. Subramanian A, Dorman S ; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S57-62.
 
9. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011 ; 11 : 76.
PubMed
10. Green H. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients : systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 ; 82 : 1052.
PubMed
11. Sagedal S. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 ; 66 : 329.
PubMed
12. The American Society of Transplantation Infectious Disease Guidelines. Am J Transplant 2009 ; 9 (Suppl 4) : S8.
 
13. 腎移植後サイトメガロウイルス感染症の診療ガイドライン 2011
 
14. Schroeder R, Michelon T, Fagundes I, et al. Antigenemia for cytomegalovirus in renal transplantation : Choosing a cut off for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 2005 ; 37 : 2781-3.
 
15. The TH, Van der Gij W, Van den Berg AP, et al. Cytomegalovirus antigenemia. Rev inf Dis 1990 ; 12 (Suppl 7) : s737-44.
 
16. Masuho Y, et al. Human monoclonal antidodies neutralizing human cytomegalovirus. J Gen Virol 1987 ; 68 : 1457-61.
 
P.204 掲載の参考文献
1. Gasink LB, et al. Low prevalence of prior streptococcus pneumoniae vaccination among potential lung transplant candidates. Chest 2006 ; 130 (1) : 218-21.
PubMed
2. 後藤憲彦, 平光高久, 渡井至彦, 打田和治. 腎移植希望患者に対する腎疾患早期からのB型肝炎ワクチンの必要性. 臨床腎移植学会症例集, 2010.
 
3. Verma A, Wade JJ, et al. Immunization issues before and after solid organ transplantation in children. Pediatr Transplant 2006 ; 10 (5) : 536-48.
PubMed
4. Danzinger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S258.
 
5. Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney Disease. Am J Transplant 2009 ; 9 (Suppl 3) : S1-155.
 
6. Avery RK, et al. Update on immunizations in solid organ transplant recipients : what clinicians need to know. Am J Transplant 2008 ; 8 : 9.
PubMed
7. Bia M, et al, KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis 2010 ; 56 (2) : 189-218.
PubMed
8. American Academy of Pediatrics. Immunocompromised children. In : Red Book : 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (ed), Elk Grove Village : American Academy of Pediatrics 2009 : 72.
 
9. DaRoza G, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization-earlier is better. Am J Kidney Dis 2003 ; 42 (6) : 1184.
PubMed
10. Kausz A, et al. The value of vaccination in CKD. Semin Dial 2004 ; 17 (1) : 9.
PubMed
11. Cohn J, et al. Immunizations for renal transplant candidates and recipients. Nat Clin Pract Nephrol 2009 ; 5 (1) : 46-53.
PubMed
12. Kumar D, et al. Invasive pneumococcal disease in solid organ transplant recipients--10-year prospective population surveillance. Am J Transplant 2007 ; 7 (5) : 1209-14.
PubMed
13. Oxman MN, et al, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 (22) : 2271-84.
PubMed
14. Takahashi M, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003 ; 21 (25-26) : 3845-53.
 
15. 後藤憲彦. 腎移植患者における帯状疱疹ワクチン予防ワクチン. 感染症学誌2011 ; 85 : 5 : 569.
 
P.211 掲載の参考文献
1. Hibberd PL, Rubin RH. Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 1990 ; 4 (1) : 123-42.
PubMed
2. 平成21年度地域保健・健康増進事業報告地域保健・健康増進事業報告. 厚生労働省. http://www.e-stat.go.jp/SG1/estat/GL02020101.do?method=listDisplay&statCode=00450025&tstatCode=000001030884&tclass1=000001043472&tclass 2=000001043479&tclass 3=&tclass 4=&tclass 5=
 
3. Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001 ; 15 (1) : 273.
PubMed
4. 国立感染症研究所感染症情報センター http://idsc.nih.go.jp/index-j.html
 
5. Danzinger-Isakov L, Kumar D, et al. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009 ; 9 (Suppl 4) : S258.
 
6. Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Peetermans WE. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008 ; 8 (2) : 332.
PubMed
7. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients : what clinicians need to know. Am J Transplant 2008 ; 8 (1) : 9.
PubMed
8. Girndt M, Pietsch M, Kohler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995 ; 26 (3) : 454.
PubMed
9. Huzly D, Neifer S, Reinke P, Schroder K, Scho?nfeld C, Hofmann T, Bienzle U. Routine immunizations in adult renal transplant recipients. Transplantation 1997 ; 63 (6) : 839.
 
10. Enke BU, Bo?kenkamp A, Offner G, Bartmann P, Brodehl. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997 ; 64 (2) : 237.
 
11. Prevots DR, Burr RK, Sutter RW, Murphy TV, Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000 ; 49 (RR-5) : 1.
 
12. Linnemann CC Jr, First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981 ; 141 (12) : 1637.
PubMed
13. Linnemann CC Jr, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986 ; 146 (8) : 1554.
PubMed
14. Dengler TJ, Strnad N, Buhring I, Zimmermann R, Girgsdies O, Kubler WE, Zielen S. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998 ; 66 (10) : 1340.
PubMed
15. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003 ; 187 (10) : 1639.
PubMed
16. Sever MS, Yildiz A, Eraksoy H, Badur S, Yuksel-Onel D, Gorc, in B, Turk S, Erkoc, R. Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron 1999 ; 81 (1) : 55.
 
17. Ison MG, Hayden FG. Viral infections in immunocompromised patients : what's new with respiratory viruses? Curr Opin Infect Dis 2002 ; 15 (4) : 355.
 
18. Scharpe J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Peetermans WE. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008 ; 8 (2) : 332.
PubMed
19. Sanchez-Fructuoso AI, Prats D, Naranjo P, Fernandez-Perez C, Gonzalez MJ, Mariano A, Gonzalez J, Figueredo MA, Martin JM, Paniagua V, Fereres J, Gomez de la Concha E, Barrientos A. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols : mycophenolate versus azathioprine. Transplantation 2000 ; 69 (3) : 436.
PubMed
20. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant 1999 ; 18 (3) : 220.
PubMed
21. Candon S, Thervet E, Lebon P, Suberbielle C, Zuber J, Lima C, Charron D, Legendre C, Chatenoud L. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009 ; 9 (10) : 2346.
PubMed
22. Schulman SL, Deforest A, Kaiser BA, Polinsky MS, Baluarte HJ. Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol 1992 ; 6 (2) : 187.
PubMed
23. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992 ; 11 (12) : 1008.
PubMed
24. Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr 1993 ; 123 (1) : 87.
PubMed
25. Furth SL, Sullivan EK, Neu AM, Tejani A, Fivush BA. Varicella in the first year after renal transplantation : a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997 ; 1 (1) : 37.
PubMed
26. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation : long-term results of vaccination. Pediatrics 1997 ; 99 (1) : 35.
PubMed
27. Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, LewisMA, Postlethwaite RJ, Smith PA, Corbitt G. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000 ; 82 (2) : 141.
 
28. Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, Kochanowicz S, Seipel KR, Levin MJ. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006 ; 6 (3) : 565.
PubMed
29. Stelzmueller I, Wiesmayr S, Swenson BR, Biebl M, Goegele H, Margreiter R, Bonatti H. Rotavirus enteritis in solid organ transplant recipients : an underestimated problem? Transpl Infect Dis 2007 ; 9 (4) : 281.
PubMed
P.218 掲載の参考文献
1. Steffen R, Ericsson CD. Special section : travel medicine. Clin Infect Dis 2000 ; 30 (5) : 809.
PubMed
2. Roukens AH, van Dissel JT, de Fijter JW, Visser LG. Health preparations and travel-related morbidity of kidney transplant recipients traveling to developing countries. Clin Transplant 2007 ; 21 : 567-70.
PubMed
3. Boggild AK, Sano M, Humar A, Salit I, Gilman M, Kain KC. Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med 2004 ; 11 : 37-43.
PubMed
4. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 ; 357 : 2601-14.
PubMed
5. http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm.
 
6. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients : Current recommendations and protocols. Clin Microbiol Rev 2003 ; 16 : 357-64.
PubMed
7. Health Information for International Travel 2003-2004. Atlanta, Georgia : Centers for Disease Control, Department of Health and Human Services, 2003.
 
8. Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 2007 ; 25 : 927-31
 
9. Stark K, Gunther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 1999 ; 180 : 2014-7.
PubMed
10. Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001 ; 71 : 477-9.
PubMed
11. Kennedy SE, Shen Y, Charlesworth JA, et al. Outcome of overseas commercial kidney transplantation : An Australian perspective. Med J Aust 2005 ; 182 : 224-7.
PubMed
12. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993 ; 42 : 1-15.
 
13. Gibbons RV, Rupprecht CE. Postexposure rabies prophylaxis in immunosuppressed patients. JAMA 2001 ; 285 : 1574-75.
PubMed
14. Conlon CP. The Immunocompromised Traveler. In : DuPont HL, Steffer R (eds) Textbook of Travel Medicine and Health. 2nd ed. B. C. Decker, 2001 : 464-9.
 
15. Kotton CN, Hibberd PL ; AST Infectious Diseases Community of Practice. Travel medicine and the solid organ transplant recipient. Am J Transplant 2009 ; 9 (Suppl 4) : S273-81.
 
P.222 掲載の参考文献
1. Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 2007 ; 44 : 857-66.
PubMed
2. Avery RK, MichaelsMG, the AST Infectious Disease Community of Practice. Strategies for safe living following solid organ transplantation. Am J Transplant 2009 ; 9 (Suppl 4) : S252-7.
 
3. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR recomm Rep 2000 ; 49 (RR-10) : 1-458, CE121-7.
 
4. Arendt RA, Morishita TY. Guide to pet care for immunocompromised. Ohiolone Fact Sheet. http://ohiolone.osu.edu
 
5. Campbell AL, Goldberg CL, Magid MS, et al. First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation. Transplantation 2006 ; 81 : 408-17.
PubMed
6. Wreghitt TG, Gray JJ, Pavel P, et al. Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients. Transpl Int 1992 ; 5 : 197-200.
PubMed
7. Alexander BD, Fishman JA. Prophylaxis of infections in solid organ transplantation. UpToDate 20.2, 2012
 
8. Pegues DA, Kubak BM, Maree CL, et al. Infections in kidney transplantation. Handbook of Kidney Transplantation 5th ed. Danovitch GM (ed), Philadelphia : Lippincott Williams & Wilkins, 2010 : 278-79.
 
9. 青木眞. 非定型抗酸菌症. レジデントのための感染症診療マニュアル 第2版, 東京 : 医学書院, 2008 : 795-8.
 
10. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients : impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007 ; 195 (5) : 756-64.
PubMed
11. Perfect JR, Dismukes WE, Dromer F, et al. Clinical Practice Guidelines for the Managementof Cryptococcal Disease : 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2010 ; 50 (3) : 291-322.
 
12. Yung AP, Grayson ML. Psittacosis--a review of 135 cases. Med J Aust 1988 ; 148 (5) : 228.
PubMed
13. Hames A, Mumford J, Hale J, et al. Salmonella Michigan soft tissue infection in an immunocompromised child. J Clin Pathol 2008 ; 61 ; 773-4.
 
14. Amreeta D, Quek KF. Non-typhoidal Salmonella bacteremia : Epidemiology, clinicai characteristics and its'association with severe immunosuppression. Ann Clin Miclobiol Antimicrobials 2009 ; 8 : 15.
 
P.226 掲載の参考文献
1. Am J Transplant 2009 ; 9 (Suppl 4) : S263-66.
 
2. Page RL, Ruscin JM, Fish D, Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001 ; 21 : 1436-43.
PubMed
3. Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin : A case report. Nephron 1995 ; 70 : 130.
PubMed
4. Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole : A pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008 ; 28 : 719-29.
PubMed
5. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 ; 45 : 954-60.
PubMed
6. Dowell JA, Stoqniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005 ; 45 : 227-33.
 
7. Lopez-Montes A, Gallego E, Lopez E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis 2004 ; 44 : e59-63.
 
8. Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograf dysfunction associated with rifampintacrolimus interaction. Ann Pharmacother 2000 ; 34 : 27-31.
 
9. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985 ; 39 : 313-4.
PubMed
10. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004 ; 6 : 1-12.
 
11. Naesens M, Kuypers DR, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination : Implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006 ; 80 : 509-21.
PubMed
P.232 掲載の参考文献
1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007 ; 357 : 2601-14.
PubMed
2. Lichtenstein IH, et al. Mycobacterial infections in renal transplant recipients : reports of five cases and review of the literature. Rev Infect Dis 1983 ; 5 (2) : 216-26.
PubMed
3. Crump JA, et al. Two decades of disseminated tuberculosis at a university medical center : the expanding role of mycobacterial blood culture. Clin Infect Dis 2003 ; 37 (8) : 1037-43.
 
4. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence versus conventional sputum smear microscopy for tuberculosis : a systematic review. Lancet Infect Dis 2006 ; 6 (9) : 570-81.
PubMed
5. Jensen PA, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare settings, 2005. MMWR Recomm Rep 2005 ; 54 (RR-17) : 1-141.
 
6. Manuel O, Kumar D. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection. Expert RevMol Diagn 2008 ; 8 : 247.
PubMed
7. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America : treatment of tuberculosis. Am J Respir Crit Care Med 2003 ; 167 : 603.
 
8. 後藤憲彦. 腎移植と結核-潜在性結核感染者に対する移植後モニタリング. 結核 2011 ; 86 (2) : 102-5.
 
9. Ison MG, et al. Viral infections in immunocompromised patients : what's new with respiratory viruses? Curr Opin Infect Dis 2002 ; 15 : 355.
 
10. Harper SA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management : clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009 ; 48 : 1003.
 
11. 三田村敬子, 川上千春, 清水英明, 他. インフルエンザの診断法. 臨床と微生物 2010 ; 37 : 569-76.
 
12. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test : a prospective, controlled clinical evaluation. J Clin Microbiol 2003 ; 41 : 2810.
 
13. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. CHEST 2007 ; 131 : 1173-80.
PubMed
14. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalised with HIV-infected patients. Emerg Infect Dis 2004 ; 10 : 1766.
PubMed
15. Dohn MN, White ML, Vigdorth EM, et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 2000 ; 162 (5) : 1617-21.
PubMed
16. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008 ; 197 (1) : 10-7.
PubMed
17. Seigel JD, Reinhart E, Jackson M, Chiarella L. The Healthcare Infection Control Advisory Committee, 2007 Guideline for Isolation Precautions : Preventing Transmission of Infectious Agents in Healthcare Settings, 2007. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf (Accessed on February 09, 2012).
 
18. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008 ; 46 (3) : 966-71.
PubMed
19. Marin M, Guris D, Chaves SS, Schmid S, Seward JF ; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 ; 56 (RR-4) : 1-40.
PubMed

書評

最近チェックした商品履歴

Loading...